Phase II Trial of Mirtazapine for Cancer-Related Cachexia and Anorexia
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
We performed an open-label single-institution phase II trial of mirtazapine (15-30 mg by mouth [po] every day [qd]), a tetracyclic antidepressant that may lead to weight gain, for 8 weeks in nondepressed patients with cancer-related cachexia/anorexia (CRCA). The primary end point was the proportion of patients who gained ≥1 kg at week 4. Secondary end points were quality of life and appetite. From June 2006 to July 2007, 17 of 58 eligible patients were enrolled. On intention-to-treat analysis at week 4, 4 of 17 patients (24%) gained 1 kg or more, 1 patient maintained weight (gain of 400 g) and 2 patients lost weight (800 g and 1.2 kg); 24% and 6% improved appetite and health-related quality of life (HQOL), respectively. Mirtazapine is a promising agent for the treatment of CRCA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients
Beck, A. T., Steer, R. A., Ball, R., & Ranieri, W. F. (1996) · Journal of Personality Assessment · doi:10.1207/s15327752jpa6703_13 · Cited by 5,965
Strasser, F., Luftner, D., Possinger, K., Ernst, G., Ruhstaller, T., Meissner, W., Ko, Y.-D., Schnelle, M., Reif, M., & Cerny, T. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1847 · Cited by 413
Kraus, T., Haack, M., Schuld, A., Hinze-Selch, D., Koethe, D., & Pollmächer, T. (2002) · Pharmacopsychiatry · doi:10.1055/s-2002-36390 · Cited by 144
Kast, R. E. (2003) · General Hospital Psychiatry · doi:10.1016/s0163-8343(03)00093-8 · Cited by 62
Cited by
Management of Cancer Cachexia: ASCO Guideline
Roeland, E. J., Bohlke, K., Baracos, V. E., Bruera, E., del Fabbro, E., Dixon, S., Fallon, M., Herrstedt, J., Lau, H., Platek, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00611 · Cited by 644
Depression in cancer: The many biobehavioral pathways driving tumor progression
Bortolato, B., Hyphantis, T. N., Valpione, S., Perini, G., Maes, M., Morris, G., Kubera, M., Köhler, C. A., Fernandes, B. S., Stubbs, B., et al. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.004 · Cited by 375
Martino, M., Rocchi, G., Escelsior, A., & Fornaro, M. (2012) · Current Neuropharmacology · doi:10.2174/157015912800604542 · Cited by 111
“Mirtazapine, in addition to representing a promising option for the treatment of cancer-related cachexia and anorexia [451, 452], has been proposed as a potential anticancer agent, both as an adjunctive treatment and as a molecule with direct effects itself, in glioblastoma [453], in osteosarcoma [454] and, more gener…”
BackgroundQuimby, J. M., & Lunn, K. F. (2013) · The Veterinary Journal · doi:10.1016/j.tvjl.2013.05.048 · Cited by 90
A Review of Therapeutic Uses of Mirtazapine in Psychiatric and Medical Conditions
Alam, A., Voronovich, Z., & Carley, J. A. (2013) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.13r01525 · Cited by 84
Metadata
- Authors
- Riechelmann, R. P., Burman, D., Tannock, I. F., Rodin, G., & Zimmermann, C.
- Venue
- American Journal of Hospice and Palliative Medicine®
- Publisher
- SAGE Publications
- Published
- 2009-09-23
- Volume
- 27
- Issue
- 2
- Pages
- 106-110
- ISSN
- 1049-9091 (ISSN-L)
- 1938-2715
- OpenAlex
- W2094865474
- Cited by
- 122
- References
- 4
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.